NCT03939767View on ClinicalTrials.gov

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

CompletedOBSERVATIONAL
Enrollment

1,563

Participants

Timeline

Start Date

May 12, 2019

Primary Completion Date

July 7, 2023

Study Completion Date

October 17, 2023

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.

Trial Locations (17)

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03939767 - Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease | Biotech Hunter | Biotech Hunter